Trial Profile
A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs ISB 1342 (Primary) ; ISB 1342 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Ichnos Sciences
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 09 Nov 2023 According to an Ichnos Sciences media release, data from this study have been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 9-12, 2023, in San Diego, California.
- 13 Dec 2022 Results (n=24; As of July 7, 2022) assessing safety and pharmacokinetics of ISB 1342 in patients with relapsed/refractory multiple myeloma, presented at the 64th American Society of Hematology Annual Meeting and Exposition.